Biolevate Raises €30M to Expand Life Sciences AI
Biolevate raised €30M Series A led by RAISE France and Orange Ventures to expand its platform for automating scientific and regulatory workflows.
The big picture: Life sciences AI company Biolevate has raised €30 million in Series A funding to expand its platform for automating scientific and regulatory workflows and support its international growth.
Why it matters:
- Operational Bottlenecks: The life sciences industry faces increasing pressure to manage complex scientific and regulatory processes as AI accelerates drug discovery and development.
- Efficiency Gains: Biolevate’s platform has demonstrated significant improvements, accelerating systematic literature reviews sixteenfold and delivering an 80% efficiency gain in regulatory intelligence.
- Global Expansion: The funding supports Biolevate’s international growth, including its expansion into the US with a new office in Boston, aiming to scale AI adoption across healthcare.
How it works:
- Agentic AI Platform: Biolevate developed an enterprise agentic AI platform that transforms scientific and regulatory knowledge into auditable workflows.
- Evidence-Grounded Outputs: The platform ensures its outputs are grounded in source evidence, allowing life sciences organizations to use AI in regulated environments while maintaining human oversight.
- Comprehensive Coverage: Initially focused on regulatory approval, the platform now covers the entire life sciences value chain, including research, clinical trials, health technology assessments, and drug discovery, capable of running up to 100,000 agents concurrently.
The catch: While Biolevate’s focus on auditable, evidence-grounded AI addresses a critical need in regulated life sciences, the market for AI solutions in this sector is becoming increasingly crowded. Competition from established tech giants and other specialized AI startups could challenge its growth trajectory, particularly as it expands into new geographies like the US, where regulatory landscapes and market dynamics differ significantly.
Key Facts
- Company: Biolevate
- Amount: €30M
- Round: Series A
- Investors: RAISE France and Orange Ventures (co-lead), MSD Global Health Innovation Fund, Station F, EQT Ventures
- Founder: Joël Belafa
- Announced: 2026-09-22
- Sector: Life Sciences AI
- Headquarters: Paris, France